Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial

Business Wire July 5, 2016

CEL-SCI to Present at LD Micro Invitational

Accesswire June 7, 2016

CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial

Business Wire June 1, 2016

CEL-SCI to Present at the Fifth Annual Marcum MicroCap Conference

Business Wire May 31, 2016

CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

Business Wire May 24, 2016

CEL-SCI Announces $5 Million Registered Direct Offering

Business Wire May 18, 2016

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

Business Wire May 10, 2016

CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial

Business Wire May 2, 2016

CEL-SCI Corporation (NYSE MKT: CVM) is Selected as Bob Flaherty's Personal Pick in Flaherty's 35th Annual Favorites of the Famous: Ten Stocks for Tomorrow!

Accesswire April 13, 2016

CEL-SCI Featured on The RedChip Money Report Airing on Newsmax TV

Business Wire April 8, 2016

CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial

Business Wire April 1, 2016

CEL-SCI Corporation's (NYSE: CVM) Global Phase III Cancer Immunotherapy Progress is Updated in Flaherty Financial Newsletter #55. Also: Wow! Dow 89,000! Sir John Templeton's Forgotten Forecast

Accesswire March 10, 2016

CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial

Business Wire March 1, 2016

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress in a New Video Interview

Business Wire February 23, 2016

CEL-SCI CEO Geert Kersten Was a Featured Guest on Fox Business' Making Money with Charles Payne

Business Wire February 18, 2016

CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

Business Wire February 9, 2016

CEL-SCI To Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Business Wire February 8, 2016

February Flaherty Financial Newsletter Features CEL-SCI Corporation's (NYSE MKT: CVM) Thrilling Phase III Cancer Immunotherapy Comeback and the Significance of the CEO's 3 Million Share Purchase

Accesswire February 4, 2016

CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference

Business Wire February 3, 2016

CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial

Business Wire February 1, 2016